'''Noxiptiline''' (brand names '''Agedal''', '''Elronon''', '''Nogedal'''), also known as '''noxiptyline''' and '''dibenzoxine''', is a [[tricyclic antidepressant]] (TCA) that was introduced in [[Europe]] in the 1970s for the treatment of [[major depressive disorder|depression]].<ref name="isbn3-88763-075-0">{{cite book | author = Swiss Pharmaceutical Society | title = Index Nominum 2000: International Drug Directory (Book with CD-ROM) | publisher = Medpharm Scientific Publishers | location = Boca Raton | year = 2000 | page = 753 | isbn = 3-88763-075-0 | oclc = | doi = | url = https://books.google.com/?id=5GpcTQD_L2oC&lpg=PA753&dq=noxiptiline&pg=PA753#v=onepage&q=&f=false}}</ref><ref name="isbn0-444-53266-8">{{cite book | author = Aronson, Jeffrey Kenneth | title = Meyler's Side Effects of Psychiatric Drugs (Meylers Side Effects) | publisher = Elsevier Science | location = Amsterdam | year = 2008 | page = 34 | isbn = 0-444-53266-8 | oclc = | doi = | url = https://books.google.com/?id=s0XYvuPVgaAC&lpg=PP1&dq=noxiptiline&pg=PA34#v=onepage&q=&f=false}}</ref><ref name="isbn0-412-54090-8">{{cite book | title = Dictionary of organic compounds | publisher = Chapman & Hall | location = London | year = 1996 | page = 4868 | isbn = 0-412-54090-8 | oclc = | doi = | url = https://books.google.com/?id=5S_uhYzKWisC&lpg=PA4868&dq=noxiptiline&pg=PA4868#v=onepage&q=&f=false}}</ref> It has [[imipramine]]-like effects,<ref name="isbn0-8493-7774-9">{{cite book | author = Mutschler, Ernst | title = Drug actions: basic principles and therapeutic aspects | publisher = Medpharm Scientific Pub | location = Stuttgart, Germany | year = 1995 | page = 127 | isbn = 0-8493-7774-9 | oclc = | doi = | url = https://books.google.com/?id=IvN4mZxraMkC&lpg=PA723&dq=noxiptiline&pg=PA127#v=onepage&q=&f=false |accessdate = January 30, 2013}}</ref> acting as a [[serotonin reuptake inhibitor|serotonin]] and [[norepinephrine reuptake inhibitor]], among other properties.<ref name="isbn3-7643-6113-1">{{cite book |author1=Ernst Jucker |author2=S. Ren |author3=Soudijn, W. |author4=Wijngaarden, I. van |author5=M. Kumari |author6=D. Poyner |author7=M. Bushfield |author8=H. Horikoshi |author9=Fujiwara, Tamenari | title = Progress in Drug Research, Volume 54 (Progress in Drug Research) | publisher = Birkhauser | location = Boston | year = 2000 | page = 81 | isbn = 3-7643-6113-1 | oclc = | doi = | url = https://books.google.com/?id=gwhdUGoO6KwC&lpg=PA80&dq=noxiptiline%20fluvoxamine&pg=PA81#v=onepage&q=&f=false}}</ref><ref name="pmid">{{cite journal |vauthors=Barth N, Manns M, Muscholl E | title = Arrhythmias and inhibition of noradrenaline uptake caused by tricyclic antidepressants and chlorpromazine on the isolated perfused rabbit heart | journal = Naunyn-Schmiedeberg's Archives of Pharmacology | volume = 288 | issue = 2–3 | pages = 215–31 | year = 1975 | pmid = 1161046| doi = 10.1007/BF00500528| url = }}</ref> Of the TCAs, noxiptiline has been described as one of the most effective, rivaling [[amitriptyline]] in clinical efficacy.<ref name="pmid1687987">{{cite journal |vauthors=Beresewicz M, Bidzińska E, Koszewska I, Puzyński S | title = [Results of using tricyclic antidepressive drugs in the treatment of endogenous depression (comparative analysis of 7 drugs)] | language = Polish | journal = Psychiatria Polska | volume = 25 | issue = 3–4 | pages = 13–8 | year = 1991 | pmid = 1687987 | doi = | url = }}</ref><ref name="pmid788000">{{cite journal |vauthors=Lingjaerde O, Asker T, Bugge A, etal | title = Noxiptilin (Agedal)--a new tricyclic antidepressant with a faster onset of action? A double-blind, multicentre comparison with amitriptyline | journal = Pharmakopsychiatrie, Neuro-Psychopharmakologie | volume = 8 | issue = 1 | pages = 26–35 |date=January 1975 | pmid = 788000 | doi = 10.1055/s-0028-1094440| url = }}</ref>
